One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-153286
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 26 |
Affiliation: Moffitt Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Hôpital Saint-Louis, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Assistance Publique – Hôpitaux de Paris, Université Côte d'Azur, Sylvester Comprehensive Cancer Center, University of Miami, University Cancer Institute Toulouse Oncopole, Hôpital Cochin, Cornell University, NewYork–Presbyterian Hospital, New York Hospital Queens, Presbyterian Hospital, Precision BioSciences (United States), Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Hôtel-Dieu de Paris, Centre Hospitalier Universitaire de Toulouse, Lille’s Cardiology Hospital
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
